Why the study?
What are the risk factors and cumulative dose thresholds for epirubicin-induced cardiotoxicity in patients with metastatic breast cancer?
What are the risk factors and cumulative dose thresholds for epirubicin-induced cardiotoxicity in patients with metastatic breast cancer?
The cumulative dosage of epirubicin that carries a 5% risk of cardiotoxicity is lower than previously assumed and depends on individual risk factors and competing mortality risks.
No takes yet. Share an insight, caveat, or question.
Suggests lower epirubicin thresholds for 5% cardiotoxicity risk than assumed; leaves optimal individualized dosing open for prospective validation.
Ryberg et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: